Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
Browsing: Pharma
ASCO: AstraZeneca’s Imfinzi and Imjud combination is effective against early liver cancer
By healthadmin
AstraZeneca is refining the rationale for Imfinzi (durvalumab) and Imjud (tremelimumab) combination therapy in liver…
Merck’s extensive clinical development program for the TROP2 antibody-drug conjugate (ADC) sac-TMT already includes 17…
With a new Phase 3 victory for Erleada (apalutamide), Johnson & Johnson offers a solution…
ASCO: Akeso’s ivonescimab outperforms PD-1 inhibitors in lung cancer chemotherapy combination therapy, reduces mortality risk by 34%
By healthadmin
This is a moment of truth for Akeso’s ivonescimab, and for many, a make-or-break test…
ASCO: Lilly links Retevmo to ‘dramatic’ outcomes in early-stage lung cancer using rare RET biomarker
By healthadmin
Embargoed: Sunday, May 31st 7am CST / 8am EST Six years after being brought to…
Pfizer appears to have once again surpassed Johnson & Johnson in the fight against PARP…
Explore the 2026 biopharma outlook focusing on M&A trends, AI in drug discovery, clinical pipelines, and regulatory strategies for pharmacologists and executives.
Insight, which is aiming to gain share in the first-line diffuse large B-cell lymphoma (DLBCL)…
With Afrezza now approved for use in children, Mankind believes it finally has the push…
ASCO: After Takeda loss, Dizal picks up the baton and takes on J&J in EGFR lung cancer subtype
By healthadmin
Editor’s note: This article will be updated after the study is published Friday afternoon. Please…